DOCSLIB.ORG

Expression of Jak3, STAT1, STAT4 and STAT6 in Inflammatory Arthritis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Expression of Jak3, STAT1, STAT4 and STAT6 in Inflammatory Arthritis ARD Online First, published on August 11, 2005 as 10.1136/ard.2005.037929 - 1 - Ann Rheum Dis: first published as 10.1136/ard.2005.037929 on 11 August 2005. Downloaded from Expression of Jak3, STAT1, STAT4 and STAT6 in inflammatory arthritis: Unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis JG Walker MBBS, FRACP MJ Ahern MBBS, MD, FRACP M Coleman MBBS, FRACP H Weedon V Papangelis B.Appl.Sci. D Beroukas B.Sc. PJ Roberts-Thomson MBBS, PhD, FRACP MD Smith MBBS, PhD, FRACP Supported by the Daw Park Research Foundation. Dr Walker’s work is supported by the National Health and Medical Research Council of Australia and the Arthritis Foundation of Australia. Address reprint requests to Jennifer Walker MBBS, FRACP, Repatriation General Hospital, Daws Rd, Daw Park 5041 South Australia. E-mail: [email protected] Ph: 08 8276 9666 http://ard.bmj.com/ Keywords: dendritic cells, rheumatoid arthritis, transcription factors. "The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its on September 30, 2021 by guest. Protected copyright. Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://ard.bmjjournals.com/misc/ifora/licenceform.shtml)." Copyright Article author (or their employer) 2005. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. - 2 - Ann Rheum Dis: first published as 10.1136/ard.2005.037929 on 11 August 2005. Downloaded from Objective. Modulation of Jak-STAT signalling may provide an effective therapeutic strategy in inflammatory arthritis (IA). We document Jak-STAT expression in a cohort of patients with active rheumatoid arthritis (RA), spondyloarthropathies (SpA) and osteoarthritis (OA) and compare these subsets with normal synovial tissue. Methods. Synovial tissue biopsies from patients with RA, OA and SpA and histologically normal tissue (n=10 in each arthritis group) were examined for the presence of Jak3, STAT1, STAT4 and STAT6 expression using immunohistochemistry. Phenotyping was performed using immunohistochemistry and immunofluorescence. Clinical and serological characteristics of RA patients expressing Jak3-STAT4 were assessed. Results. STAT1, STAT4 and Jak3 protein expression was generally increased in IA. In contrast, STAT6 expression was relatively heterogeneous. A subpopulation of CD1a positive dendritic cells unique to seropositive RA patients was detected. These cells showed intense protein expression for Jak3, STAT4 and STAT6. Conclusion. CD1a positive dendritic cells intensely express Jak3, STAT4 and STAT6 in seropositive RA tissue and may be an alternative marker for dendritic cells in their early stages of activation as well as providing a tool for identifying RA at the level of the synovium. Jak3 inhibition may be a potential therapeutic target to prevent dendritic cell maturation in RA. STAT1 expression is increased in inflammatory arthritis, suggesting that its pro-apoptotic and anti-inflammatory effects are unable to effectively counteract inflammation. STAT6 expression is heterogeneous in synovium, suggesting a possible homeostatic role in addition to any anti-inflammatory effects. http://ard.bmj.com/ on September 30, 2021 by guest. Protected copyright. - 3 - Ann Rheum Dis: first published as 10.1136/ard.2005.037929 on 11 August 2005. Downloaded from Rheumatoid arthritis (RA) is a chronic inflammatory disease, primarily of synovium[1]. Cytokines have important roles in perpetuating inflammation, particularly macrophage- derived tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1). Antibodies against TNFα and the use of IL-1 receptor antagonist have successfully suppressed inflammation in many RA patients but only 60% of patients will obtain a partial response and a minority experience no benefit[2]. The study of transcription factor pathways may provide an explanation for the variable responses to IL-1 and TNFα antagonists. The smaller molecules in these pathways make an attractive alternative therapeutic target because pharmaceuticals have the potential to be orally bioavailable. In addition, only a few inducible factors seem to play a pivotal role in the regulation of inflammatory genes (e.g. activator protein-1 (AP-1), CCAT/enhancer-binding proteins (C/EBP’s), STATs, NF-AT (nuclear factor of activated T cells) and NF-κΒ (nuclear factor-κΒ)[3]. The janus kinase and Signal Transducer and Activator of Transcription (Jak-STAT) pathway is the signalling target of a multitude of cytokines, including IFNγ, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12 and IL-15, all of which are thought to have biologically significant roles in rheumatoid synovial inflammation[4, 5]. There are seven identified STATs and preliminary work in human synovial tissue suggests that 1. STAT1 expression and activity are increased in RA synovium, at least in those with active disease[6, 7], 2. STAT3 promotes survival of RA synovial fibroblasts[8], 3. STAT4 is expressed in RA synovium[9] and 4. IL-4 STAT mRNA (IL-4 primarily signals through STAT6) is increased in RA tissue[10]. In addition, murine arthritis knockout models suggest that IL-12, signalling through a http://ard.bmj.com/ STAT4 pathway is required for the development of proteoglycan-induced inflammatory arthritis while IL-4, signalling through STAT6, has an anti-inflammatory effect[11]. Generally STATs confer signalling specificity, while Jaks are more widely expressed but Jak3 expression is mostly limited to haematopoietic cell lines and as such, it is a potential on September 30, 2021 by guest. Protected copyright. therapeutic target in patients with autoimmune disease. There is no published work investigating Jak3 expression in human synovial tissue although it has been identified as a potential therapeutic target in autoimmune disease. The immunomodulatory effects of Jak3 extend beyond its role in STAT activation as it is (i) phosphorylated during dendritic cell activation through the CD40-CD154 ligand [12] and (ii) phosphorylated upon T cell receptor (TCR) stimulation in murine models and therefore may play a direct role in T cell activation[13]. With the exception of STAT1, most published research investigating Jak-STAT in inflammatory arthritis has been limited to work in synovial fibroblasts or tissue obtained at the time of joint replacement surgery, often without detailed information regarding clinical activity. Therefore, results must be interpreted with caution because the clinical and histological features of RA alter significantly depending on disease activity[14]. In addition, work in synovial fibroblasts cannot be extrapolated to macrophages or - 4 - Ann Rheum Dis: first published as 10.1136/ard.2005.037929 on 11 August 2005. Downloaded from lymphocytes, with both of these cell populations likely to have important pathogenic roles in RA. We hypothesized that Jak-STAT would be differentially expressed in RA compared with other forms of arthritis and now report on the protein expression of STAT1, STAT4, STAT6 and Jak3 in a series of patients with RA, spondyloarthritis (SpA), osteoarthritis (OA) and normal controls using synovial tissue taken from patients with clinically active disease. MATERIALS AND METHODS Patients. Synovial tissue was obtained from 38 subjects, including 10 patients with RA, 10 patients with spondyloarthritis(SpA), 10 patients with osteoarthritis (OA) and 8 control subjects. Control specimens were obtained from patients undergoing knee or ankle joint arthroscopy for undiagnosed joint pain, who were observed to have non- inflamed synovium at the time of arthroscopy and on subsequent histological analysis. SpA subjects consisted of 5 patients with undifferentiated SpA, 4 Psoriatic arthritis and 1 Ankylosing spondylitis. The diagnoses of RA and OA conformed to 1987 American College of Rheumatology criteria[15, 16]. Tables 1 and 2 summarise clinical details of individual RA and SpA patients, and provides conglomerate details of OA and normal control patients. All studies were approved by the Ethics Committee of the Repatriation General Hospital. Arthroscopic Biopsies. Synovial membrane samples were obtained from involved joints (knee, wrist or ankle) of patients with RA, SpA , and OA under direct vision using a 2.7mm mini-arthroscope (Dyonics, Andover, MA, USA) and standard approaches as previously described[17]. Normal specimens were obtained from patients undergoing http://ard.bmj.com/ arthroscopy for undiagnosed joint pain at a sports medicine facility who were observed to have non-inflamed synovium at the time of arthroscopy and on subsequent histological analysis. Samples were frozen in Tissue Tek O.C.T. compound (Miles Diagnostics) and stored at -80°C. Immunohistochemistry. Antibodies are listed in Table 3. Cryosections (4µm) were on September 30, 2021 by guest. Protected copyright. fixed in ice-cold acetone for 4 minutes. Sections were brought to room temperature, washed in phosphate buffered saline (PBS) and endogenous peroxidase activity was inhibited using 1%H202 and 0.1% Sodium Azide in PBS. Primary antibody was applied for 2 hours (1.5 hours for STAT1) at room temperature. (Control sections incubated with diluent PBS/1%BSA). HRP-conjugated goat anti-rabbit antibody was applied for 30 minutes, followed by HRP-conjugated swine anti-goat for 30
Load more

Recommended publications
  • The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
    Published OnlineFirst October 26, 2016; DOI: 10.1158/2159-8290.CD-15-1263 RESEARCH ARTICLE The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer Jennifer L. Bishop1, Daksh Thaper1,2, Sepideh Vahid1,2, Alastair Davies1, Kirsi Ketola1, Hidetoshi Kuruma1, Randy Jama1, Ka Mun Nip1,2, Arkhjamil Angeles1, Fraser Johnson1, Alexander W. Wyatt1,2, Ladan Fazli1,2, Martin E. Gleave1,2, Dong Lin1, Mark A. Rubin3, Colin C. Collins1,2, Yuzhuo Wang1,2, Himisha Beltran3, and Amina Zoubeidi1,2 ABSTRACT Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain elusive. Using a unique model of AR pathway inhibitor–resistant prostate cancer, we identified AR-dependent control of the neural transcription factor BRN2 (encoded by POU3F2) as a major driver of NEPC and aggressive tumor growth, both in vitro and in vivo. Mecha- nistic studies showed that AR directly suppresses BRN2 transcription, which is required for NEPC, and BRN2-dependent regulation of the NEPC marker SOX2. Underscoring its inverse correlation with clas- sic AR activity in clinical samples, BRN2 expression was highest in NEPC tumors and was significantly increased in castration-resistant prostate cancer compared with adenocarcinoma, especially in patients with low serum PSA. These data reveal a novel mechanism of AR-dependent control of NEPC and suggest that targeting BRN2 is a strategy to treat or prevent neuroendocrine differentiation in prostate tumors. SIGNIFICANCE: Understanding the contribution of the AR to the emergence of highly lethal, drug- resistant NEPC is critical for better implementation of current standard-of-care therapies and novel drug design.
    [Show full text]
  • Stat4 Consensus and Mutant Oligonucleotides
    SANTA CRUZ BIOTECHNOLOGY, INC. Stat4 Consensus and Mutant Oligonucleotides BACKGROUND PRODUCT Electrophoretic mobility shift assays (EMSAs), also known as gel shift assays, Stat4 CONSENSUS OLIGONUCLEOTIDE: sc-2569 provide a relatively straightforward and sensitive method for studying bind- ■ binding site for Stat4 (3) ing interactions between transcription factors and consensus DNA binding elements. For such studies, DNA probes are provided as double-stranded 5’ — GAG CCT GA T TTC CCC GAA AT G ATG AGC TAG — 3’ oligonucleotides designed with 5' OH blunt ends to facilitate labeling to high 3’ — CTC GGA C T A AAG GGG CTT TA C TAC TCG ATC — 5’ specific activity with polynucleotide kinase. These are constructed both with Stat4 MUTANT OLIGONUCLEOTIDE: sc-2570 specific DNA binding consensus sequences for various transcription factors ■ identical to sc-2569 with the exception of a “CCC” “TTT” substitution in and as control or “mutant” probes in which one or more nucleotides mapping → the Stat4 binding motif (3) within the consensus binding site has been substituted. 5’ — GAG CCT GA T TTC TTT GAA AT G ATG AGC TAG — 3’ REFERENCES 3’ — CTC GGA C T A AAG AAA CTT TA C TAC TCG ATC — 5’ 1. Dignam, J.D., et al. 1983. Accurate transcription initiation by RNA poly- merase II in a soluble extract from isolated mammalian nuclei. Nucleic SELECT PRODUCT CITATIONS Acids Res. 11: 1475-1489. 1. Ahn, H.J., et al. 1998. Requirement for distinct Janus kinases and STAT 2. Murre, C., et al. 1991. B cell- and myocyte-specific E2-box-binding factors proteins in T cell proliferation versus IFN-g production following IL-12 contain E12/E47-like subunits.
    [Show full text]
  • Quantitative Modelling Explains Distinct STAT1 and STAT3
    bioRxiv preprint doi: https://doi.org/10.1101/425868; this version posted September 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title Quantitative modelling explains distinct STAT1 and STAT3 activation dynamics in response to both IFNγ and IL-10 stimuli and predicts emergence of reciprocal signalling at the level of single cells. 1,2, 3 1 1 1 1 1 2 Sarma U , Maitreye M , Bhadange S , Nair A , Srivastava A , Saha B , Mukherjee D . 1: National Centre for Cell Science, NCCS Complex, Ganeshkhind, SP Pune University Campus, Pune 411007, India. 2 : Corresponding author. [email protected] , [email protected] 3: Present address. Labs, Persistent Systems Limited, Pingala – Aryabhata, Erandwane, Pune, 411004 India. bioRxiv preprint doi: https://doi.org/10.1101/425868; this version posted September 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Cells use IFNγ-STAT1 and IL-10-STAT3 pathways primarily to elicit pro and anti-inflammatory responses, respectively. However, activation of STAT1 by IL-10 and STAT3 by IFNγ is also observed. The regulatory mechanisms controlling the amplitude and dynamics of both the STATs in response to these functionally opposing stimuli remains less understood. Here, our experiments at cell population level show distinct early signalling dynamics of both STAT1 and STAT3(S/1/3) in responses to IFNγ and IL-10 stimulation.
    [Show full text]
  • IRF8 Regulates Gram-Negative Bacteria–Mediated NLRP3 Inflammasome Activation and Cell Death
    IRF8 Regulates Gram-Negative Bacteria− Mediated NLRP3 Inflammasome Activation and Cell Death This information is current as Rajendra Karki, Ein Lee, Bhesh R. Sharma, Balaji Banoth of September 25, 2021. and Thirumala-Devi Kanneganti J Immunol published online 23 March 2020 http://www.jimmunol.org/content/early/2020/03/20/jimmun ol.1901508 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2020/03/20/jimmunol.190150 Material 8.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2020 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published March 23, 2020, doi:10.4049/jimmunol.1901508 The Journal of Immunology IRF8 Regulates Gram-Negative Bacteria–Mediated NLRP3 Inflammasome Activation and Cell Death Rajendra Karki,*,1 Ein Lee,*,†,1 Bhesh R. Sharma,*,1 Balaji Banoth,* and Thirumala-Devi Kanneganti* Inflammasomes are intracellular signaling complexes that are assembled in response to a variety of pathogenic or physiologic stimuli to initiate inflammatory responses.
    [Show full text]
  • Reduced Expression of IL-12 Receptor B2 and IL-18 Receptor a Genes in Natural Killer Cells and Macrophages Derived from B6-Mi/Mi Mice
    Laboratory Investigation (2005) 85, 146–153 & 2005 USCAP, Inc All rights reserved 0023-6837/05 $30.00 www.laboratoryinvestigation.org Reduced expression of IL-12 receptor b2 and IL-18 receptor a genes in natural killer cells and macrophages derived from B6-mi/mi mice Tatsuki R Kataoka1,2, Nobuyasu Komazawa3, Keisuke Oboki1, Eiichi Morii1 and Toru Nakano1,4 1Department of Pathology, Medical School/Graduate School of Frontier Bioscience, Osaka University, Osaka, Japan; 2Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; 3Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan and 4Department of Molecular Cell Biology, Research Institute for Microbial Disease, Osaka University, Osaka, Japan The mi transcriptional factor (MITF) is a basic helix–loop–helix leucine zipper-type transcriptional factor. The mi mutant allele encodes an abnormal MITF, in which one out of four consecutive arginines is deleted in the basic domain. The VGA-9-tg (tg) allele is another mutant allele and considered to be a null mutant allele. C57BL/6 (B6)- mi/mi mice showed abnormal phenotypes of natural killer (NK) cells and macrophages, whereas B6-tg/tg mice did not. The expression levels of the genes for the interleukin-12 receptor (IL-12R) b2 and IL-18Ra were reduced in both the NK cells and macrophages of B6-mi/mi mice, while the expression levels of the corresponding genes in B6-tg/tg mice were unaffected. The B6-mi/mi NK cells and B6-mi/mi macrophages showed impaired responses to stimulation with IL-12, IL-18, and IL-12 plus IL-18 stimulation.
    [Show full text]
  • STAT1 Signalling Predicts Response to Chemotherapy in Oestrogen Receptor-Negative Breast Cancer
    FULL PAPER British Journal of Cancer (2016) 114, 177–187 | doi: 10.1038/bjc.2015.398 Keywords: STAT1; ER-negative breast cancer; IFN; chemotherapy; predictive signature Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer Marie-Emmanuelle Legrier1, Ivan Bie` che2, Julie Gaston1, Arnaud Beurdeley1, Vanessa Yvonnet1, Olivier De´as1, Aure´ lie Thuleau3, Sophie Chaˆ teau-Joubert4, Jean-Luc Servely4,5, Sophie Vacher2, Myriam Lassalle1, Ste´ phane Depil6, Gordon C Tucker6, Jean-Jacques Fontaine4, Marie-France Poupon1, Sergio Roman-Roman3, Jean-Gabriel Judde1, Didier Decaudin3,7, Stefano Cairo*,1,8,9 and Elisabetta Marangoni*,3,9 1XenTech, 4 rue Pierre Fontaine, Evry 91000, France; 2Genetics Department, Hospital, Institut Curie, 26 rue d’Ulm, Paris 75005, France; 3Translational Research Department, Institut Curie, 26 rue d’Ulm, Paris 75005, France; 4Department of Pathology, Veterinary School of Alfort, Maisons-Alfort 94704, France; 5INRA, Phase Department, Nouzilly, France; 6Institut de Recherches Servier, PIT Oncology, Croissy-sur-Seine 78290, France; 7Medical Oncology Department, Institut Curie, 26 rue d’Ulm, Paris 75005, France and 8University of Ferrara, LTTA Centre, Department of Morphology, Surgery and Experimental Medicine, Ferrara, Italy Background: Oestrogen receptor-negative (ER À ) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and relapse occurs with high frequency. The aim of this work was to analyse the molecular characteristics of residual tumours and early response to chemotherapy in patient-derived xenografts (PDXs) of breast cancer. Methods: Gene and protein expression profiles were analysed in a panel of ER À breast cancer PDXs before and after chemotherapy treatment.
    [Show full text]
  • Targeting Il13ralpha2 Activates STAT6-TP63 Pathway to Suppress Breast Cancer Lung Metastasis Panagiotis Papageorgis1,2,3*, Sait Ozturk2, Arthur W
    Papageorgis et al. Breast Cancer Research (2015) 17:98 DOI 10.1186/s13058-015-0607-y RESEARCH ARTICLE Open Access Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis Panagiotis Papageorgis1,2,3*, Sait Ozturk2, Arthur W. Lambert2, Christiana M. Neophytou1, Alexandros Tzatsos4, Chen K. Wong2, Sam Thiagalingam2*† and Andreas I. Constantinou1*† Abstract Introduction: Basal-like breast cancer (BLBC) is an aggressive subtype often characterized by distant metastasis, poor patient prognosis, and limited treatment options. Therefore, the discovery of alternative targets to restrain its metastatic potential is urgently needed. In this study, we aimed to identify novel genes that drive metastasis of BLBC and to elucidate the underlying mechanisms of action. Methods: An unbiased approach using gene expression profiling of a BLBC progression model and in silico leveraging of pre-existing tumor transcriptomes were used to uncover metastasis-promoting genes. Lentiviral- mediated knockdown of interleukin-13 receptor alpha 2 (IL13Ralpha2) coupled with whole-body in vivo bioluminescence imaging was performed to assess its role in regulating breast cancer tumor growth and lung metastasis. Gene expression microarray analysis was followed by in vitro validation and cell migration assays to elucidate the downstream molecular pathways involved in this process. Results: We found that overexpression of the decoy receptor IL13Ralpha2 is significantly enriched in basal compared with luminal primary breast tumors as well as in a subset of metastatic basal-B breast cancer cells. Importantly, breast cancer patients with high-grade tumors and increased IL13Ralpha2 levels had significantly worse prognosis for metastasis-free survival compared with patients with low expression.
    [Show full text]
  • Estrogen Receptors and Ubiquitin Proteasome System: Mutual Regulation
    biomolecules Review Estrogen Receptors and Ubiquitin Proteasome System: Mutual Regulation Irina V. Kondakova 1 , Elena E. Shashova 1, Evgenia A. Sidenko 1, Tatiana M. Astakhova 2, Liudmila A. Zakharova 2 and Natalia P. Sharova 2,* 1 Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634009 Tomsk, Russia; [email protected] (I.V.K.); [email protected] (E.E.S.); [email protected] (E.A.S.) 2 Koltzov Institute of Developmental Biology, Russian Academy of Sciences, 26 Vavilov Street, 119334 Moscow, Russia; [email protected] (T.M.A.); [email protected] (L.A.Z.) * Correspondence: [email protected]; Tel.: +7-499-135-7674; Fax: +7-499-135-3322 Received: 16 February 2020; Accepted: 25 March 2020; Published: 26 March 2020 Abstract: This review provides information on the structure of estrogen receptors (ERs), their localization and functions in mammalian cells. Additionally, the structure of proteasomes and mechanisms of protein ubiquitination and cleavage are described. According to the modern concept, the ubiquitin proteasome system (UPS) is involved in the regulation of the activity of ERs in several ways. First, UPS performs the ubiquitination of ERs with a change in their functional activity. Second, UPS degrades ERs and their transcriptional regulators. Third, UPS affects the expression of ER genes. In addition, the opportunity of the regulation of proteasome functioning by ERs—in particular, the expression of immune proteasomes—is discussed. Understanding the complex mechanisms underlying the regulation of ERs and proteasomes has great prospects for the development of new therapeutic agents that can make a significant contribution to the treatment of diseases associated with the impaired function of these biomolecules.
    [Show full text]
  • Entinostat Augments NK Cell Functions Via Epigenetic Upregulation of IFIT1-STING-STAT4 Pathway
    www.oncotarget.com Oncotarget, 2020, Vol. 11, (No. 20), pp: 1799-1815 Research Paper Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway John M. Idso1, Shunhua Lao1, Nathan J. Schloemer1,2, Jeffrey Knipstein2, Robert Burns3, Monica S. Thakar1,2,* and Subramaniam Malarkannan1,2,4,5,* 1Laboratory of Molecular Immunology and Immunotherapy, Blood Research Institute, Versiti, Milwaukee, WI, USA 2Division of Pediatric Hematology-Oncology-BMT, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA 3Bioinformatics Core, Blood Research Institute, Versiti, Milwaukee, WI, USA 4Divson of Hematology-Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA 5Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA *Co-senior authors Correspondence to: Monica S. Thakar, email: [email protected] Subramaniam Malarkannan, email: [email protected] Keywords: NK cells; histone deacetylase inhibitor; Ewing sarcoma; rhabdomyosarcoma; immunotherapy Received: September 10, 2019 Accepted: March 03, 2020 Published: May 19, 2020 Copyright: Idso et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Histone deacetylase inhibitors (HDACi) are an emerging cancer therapy; however, their effect on natural killer (NK) cell-mediated anti-tumor responses remain unknown. Here, we evaluated the impact of a benzamide HDACi, entinostat, on human primary NK cells as well as tumor cell lines. Entinostat significantly upregulated the expression of NKG2D, an essential NK cell activating receptor. Independently, entinostat augmented the expression of ULBP1, HLA, and MICA/B on both rhabdomyosarcoma and Ewing sarcoma cell lines.
    [Show full text]
  • A Dual Cis-Regulatory Code Links IRF8 to Constitutive and Inducible Gene Expression in Macrophages
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press A dual cis-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages Alessandra Mancino,1,3 Alberto Termanini,1,3 Iros Barozzi,1 Serena Ghisletti,1 Renato Ostuni,1 Elena Prosperini,1 Keiko Ozato,2 and Gioacchino Natoli1 1Department of Experimental Oncology, European Institute of Oncology (IEO), 20139 Milan, Italy; 2Laboratory of Molecular Growth Regulation, Genomics of Differentiation Program, National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland 20892, USA The transcription factor (TF) interferon regulatory factor 8 (IRF8) controls both developmental and inflammatory stimulus-inducible genes in macrophages, but the mechanisms underlying these two different functions are largely unknown. One possibility is that these different roles are linked to the ability of IRF8 to bind alternative DNA sequences. We found that IRF8 is recruited to distinct sets of DNA consensus sequences before and after lipopolysaccharide (LPS) stimulation. In resting cells, IRF8 was mainly bound to composite sites together with the master regulator of myeloid development PU.1. Basal IRF8–PU.1 binding maintained the expression of a broad panel of genes essential for macrophage functions (such as microbial recognition and response to purines) and contributed to basal expression of many LPS-inducible genes. After LPS stimulation, increased expression of IRF8, other IRFs, and AP-1 family TFs enabled IRF8 binding to thousands of additional regions containing low-affinity multimerized IRF sites and composite IRF–AP-1 sites, which were not premarked by PU.1 and did not contribute to the basal IRF8 cistrome.
    [Show full text]
  • IL-17-Secreting Th Cells Stat3 and Stat4 Direct Development Of
    Stat3 and Stat4 Direct Development of IL-17-Secreting Th Cells Anubhav N. Mathur, Hua-Chen Chang, Dimitrios G. Zisoulis, Gretta L. Stritesky, Qing Yu, John T. O'Malley, This information is current as Reuben Kapur, David E. Levy, Geoffrey S. Kansas and Mark of September 29, 2021. H. Kaplan J Immunol 2007; 178:4901-4907; ; doi: 10.4049/jimmunol.178.8.4901 http://www.jimmunol.org/content/178/8/4901 Downloaded from References This article cites 38 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/178/8/4901.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Stat3 and Stat4 Direct Development of IL-17-Secreting Th Cells1 Anubhav N. Mathur,2*† Hua-Chen Chang,2*† Dimitrios G. Zisoulis,‡ Gretta L.
    [Show full text]
  • Interferons Inhibit Activation of STAT6 by Interleukin 4 in Human Monocytes by Inducing SOCS-1 Gene Expression
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 10800–10805, September 1999 Immunology Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression HAROLD L. DICKENSHEETS*, CHANDRASEKAR VENKATARAMAN†,ULRIKE SCHINDLER†, AND RAYMOND P. DONNELLY*‡ *Division of Cytokine Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892; and †Tularik, Inc., South San Francisco, CA 94080 Edited by William E. Paul, National Institutes of Health, Bethesda, MD, and approved July 8, 1999 (received for review February 16, 1999) ABSTRACT Interferons (IFNs) inhibit induction by IL-4 12), 15-lipoxygenase (15-LO) (13, 14), IL-1 receptor antago- of multiple genes in human monocytes. However, the mecha- nist (IL-1ra) (15–17), and types I and II IL-1 receptors (IL-1R) nism by which IFNs mediate this inhibition has not been (18, 19). Type I IFNs (IFN-␣ and IFN-␤) and type II IFN defined. IL-4 activates gene expression by inducing tyrosine (IFN-␥) inhibit IL-4͞IL-13-induced gene expression in mono- phosphorylation, homodimerization, and nuclear transloca- cytes and B cells. For example, IFN-␥ suppresses IgE synthesis tion of the latent transcription factor, STAT6 (signal trans- by IL-4-stimulated B cells (20–22). IFNs also inhibit IL-4- ducer and activator of transcription-6). STAT6-responsive induced CD23 expression in both B cells (23, 24) and mono- elements are characteristically present in the promoters of cytes (25, 26). Furthermore, IFN-␥ inhibits IL-4- and IL-13- IL-4-inducible genes. Because STAT6 activation is essential induced expression of 15-LO and IL-1ra in monocytes (13, 14, for IL-4-induced gene expression, we examined the ability of 27).
    [Show full text]